← Back to home

Locally advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations

Clinical trials for Locally advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations explained in plain language.

Never miss a new study

Get alerted when new Locally advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations trials appear

Sign up with your email to follow new studies for Locally advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug combo aims to outsmart resistant lung cancer

Disease control Recruiting now

This Phase II trial tests a combination of two drugs, JS212 and JS111, in about 35 people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to prior treatment. The study will first find the safest dose, then check how well the c…

Matched conditions: LOCALLY ADVANCED, METASTATIC, OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS

Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control

Last updated Jul 09, 2026 00:00 UTC

Locally advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations

Get alerted when new Locally advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations trials appear

New drug combo aims to outsmart resistant lung cancer